Breakpoint analysis of IKZF1 gene deletions in patients with B-cell precursor acute lymphoblastic leukemia

Authors

  • Maryia A. Keraz Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus
  • Darya A. Bogatenkova Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus
  • Volha S. Vshyukova Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus
  • Alexander N. Meleshko Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus

Keywords:

IKZF1, Ikaros, cryptic recombination signal sequences, cRSS, B-cell precursor acute lymphoblastic leukemia, BCP-ALL, breakpoints, recombination sites, hotspots, deletions
Supporting Agencies
This work was carried out within the framework of the state scientific and technical programme «Scientific and technical provision of quality and accessibility of medical services» (subprogramme «Malignant tumors», assignment «To develop and implement a method of molecular genetic diagnostics of BCR-ABL1-like acute lymphoblastic leukemia and evaluate prognosis indicators for this type of leukemia in pediatric patients, adolescents and “young” adults», contract No. 02.14/2020).

Abstract

In addition to the long-known diagnostically significant rearrangements in B-cell precursor acute lymphoblastic leukemia, such as BCR::ABL1, TCF3::PBX1 (E2A::PBX1) and KMT2A (MLL), mutations in genes of transcription factors, which controls lymphoid differentiation, primarily mutations in the IKZF1 gene, are of considerable interest in predicting the course of the disease. The IKZF1 gene encodes a DNA-binding protein Ikaros, which is a key transcription factor that regulates early steps in the differentiation of T- and B-lymphocytes, NK cells and dendritic cells. In B-cell precursor acute lymphoblastic leukemia, the most common genetic events involving the IKZF1 gene are intragenic deletions that result in the loss of several exons. These deletions are observed in pediatric and adult patients with B-cell precursor acute lymphoblastic leukemia, with a higher prevalence in cases where there is a BCR::ABL1 translocation. There are also known splicing disorders expressed in increased expression of short IKZF1 gene transcripts (isoforms). However, in the vast majority of cases, increased expression of short isoforms is a consequence of intragenic deletion. These molecular genetic changes contribute to the dysregulation of lymphoid differentiation and are associated with a poor prognosis for patients with B-cell precursor acute lymphoblastic leukemia. Understanding the genetic alterations in key transcription factors, such as Ikaros, can provide valuable insights into the biology of B-cell precursor acute lymphoblastic leukemia and help in predicting the clinical outcomes of patients with this disease.

Author Biographies

  • Maryia A. Keraz, Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus

    junior researcher at the laboratory of genetic biotechnologies

  • Darya A. Bogatenkova, Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus

    junior researcher at the laboratory of molecular genetic research

  • Volha S. Vshyukova, Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus

    PhD (biology); leading researcher at the laboratory of genetic biotechnologies and scientific secretary

  • Alexander N. Meleshko, Republican Scientific and Practical Center for Children’s Oncology, Hematology and Immunology, 43 Frunzienskaja Street, Barawliany 223053, Barawlianski sielsaviet, Minsk District, Belarus

    PhD (biology); leading researcher at the laboratory of genetic biotechnologies

References

  1. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–2539. DOI: 10.3324/hae¬ matol.2020.247031.
  2. Bhojwani D, Yang JJ, Pui C-H. Biology of childhood acute lymphoblastic leukemia. Pediatric Clinics of North America. 2015; 62(1):47–60. DOI: 10.1016/j.pcl.2014.09.004.
  3. Mullighan CG. Genomic characterization of childhood acute lymphoblastic leukemia. Seminars in Hematology. 2013;50(4):314–324. DOI: 10.1053/j.seminhematol.2013.10.001.
  4. Vairy S, Tran TH. IKZF1 alterations in acute lymphoblastic leukemia: the good, the bad and the ugly. Blood Reviews. 2020;44:100677. DOI: 10.1016/j.blre.2020.100677.
  5. Stanulla M, Cavé H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2020;135(4):252–260. DOI: 10.1182/blood.2019000813.
  6. Iacobucci I, Kimura S, Mullighan CG. Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. Journal of Clinical Medicine. 2021;10(17):3792. DOI: 10.3390/jcm10173792.
  7. Klco JM, Mullighan CG. Advances in germline predisposition to acute leukaemias and myeloid neoplasms. Nature Reviews Cancer. 2021;21(2):122–137. DOI: 10.1038/s41568-020-00315-z.
  8. Vshyukova VS, Krasko OV, Yanchanka DA, Meleshko AN. Aberrant IKZF1 gene as relapse predictor in standard‐risk pediatric patients with B‐cell precursor acute lymphoblastic leukaemia. International Journal of Laboratory Hematology. 2022;44(4):769–776. DOI: 10.1111/ijlh.13853.
  9. Olsson L, Johansson B. Ikaros and leukaemia. British Journal of Haematology. 2015;169(4):479–491. DOI: 10.1111/bjh.13342.
  10. Vshivkova VS, Meleshko AN. The role of Ikaros transcriptional factor in normal hematopoiesis and leukemogenesis: biological and clinical aspects. Advances in Molecular Oncology. 2015;2(1):13–26. Russian. DOI: 10.17650/2313-805X.2015.2.1.013-026.
  11. Yadav V, Ganesan P, Veeramani R, Dinesh Kumar V. Philadelphia-like acute lymphoblastic leukemia: a systematic review. Clinical Lymphoma Myeloma and Leukemia. 2021;21(1):e57 – e65. DOI: 10.1016/j.clml.2020.08.011.
  12. Xia R, Cheng Y, Han X, Wei Y, Wei X. Ikaros proteins in tumor: current perspectives and new developments. Frontiers in Molecular Biosciences. 2021;8:788440. DOI: 10.3389/fmolb.2021.788440.
  13. Affar M, Bottardi S, Quansah N, Lemarié M, Ramón AC, Affar EB, et al. Ikaros: from chromatin organization to transcriptional elongation control. Cell Death & Differentiation [Internet]. 2023 August 24 [cited 2024 March 17]. Available from: https://www.nature.com/articles/s41418-023-01212-2. Epub ahead of print. DOI: 10.1038/s41418-023-01212-2.
  14. Wang Y, Cheng W, Zhang Yv, Zhang Yu, Sun T, Zhu Y, et al. Identification of IKZF1 genetic mutations as new molecular subtypes in acute myeloid leukaemia. Clinical and Translational Medicine. 2023;13(6):e1309. DOI: 10.1002/ctm2.1309.
  15. Merelli I, Guffanti A, Fabbri M, Cocito A, Furia L, Grazini U, et al. RSSsite: a reference database and prediction tool for the identification of cryptic recombination signal sequences in human and murine genomes. Nucleic Acids Research. 2010;38(supplement 2):W262 – W267. DOI: 10.1093/nar/gkq391.

Downloads

Additional Files

Published

2024-11-18

Issue

No. 3 (2024): Experimental Biology and Biotechnology

Section

Genetics and Molecular Biology

License

The authors who are published in this journal agree to the following:

  1. The authors retain copyright on the work and provide the journal with the right of first publication of the work on condition of license Creative Commons Attribution-NonCommercial. 4.0 International (CC BY-NC 4.0).
  2. The authors retain the right to enter into certain contractual agreements relating to the non-exclusive distribution of the published version of the work (e.g. post it on the institutional repository, publication in the book), with the reference to its original publication in this journal.
  3. The authors have the right to post their work on the Internet (e.g. on the institutional store or personal website) prior to and during the review process, conducted by the journal, as this may lead to a productive discussion and a large number of references to this work. (See The Effect of Open Access.)

How to Cite

Keraz, M. A. ., Bogatenkova, D. A. ., Vshyukova, V. S. ., & Meleshko, A. N. . (2024). Breakpoint analysis of IKZF1 gene deletions in patients with B-cell precursor acute lymphoblastic leukemia. Experimental Biology and Biotechnology, 3, 50-58. https://journals.bsu.by/index.php/biology/article/view/6259